Tools   Select Another Resource Report Type

http://www.cancer.org/

The American Cancer Society is the nationwide, community-based, voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives, and diminishing suffering from cancer, through research, education, advocacy, and service. Together with our millions of supporters, the American Cancer Society (ACS) saves lives and creates a world with less cancer and more birthdays by helping people stay well, helping people get well, by finding cures, and by fighting back. Headquartered in Atlanta, Georgia, the ACS has 12 chartered Divisions, more than 900 local offices nationwide, and a presence in more than 5,100 communities.

Proper citation: American Cancer Society (RRID:SCR_005756) Copy   

•   Source: SciCrunch Registry

http://www.celgene.com

An American global biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD). (Adapted from Wikipedia) There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.

Proper citation: Celgene (RRID:SCR_002955) Copy   

•   Source: SciCrunch Registry

http://cgems.cancer.gov

The project began as a pilot study to identify inherited genetic susceptibility to prostate and breast cancer. CGEMS has developed into a robust research program involving genome-wide association studies (GWASs) for a number of cancers to identify common genetic variants that affect a person''s risk of developing cancer. In collaboration with extramural scientists, NCI''s Division of Cancer Epidemiology and Genetics (DCEG) has carried out genome-wide scans for breast, prostate, pancreatic, and lung cancers, while a GWAS of bladder cancer is currently underway. By making the data available to both intramural and extramural research scientists, as well as those in the private sector through rapid posting, NIH can leverage its resources to ensure that the dramatic advances in genomics are incorporated into rigorous population-based studies. Ultimately, findings from these studies may yield new preventive, diagnostic, and therapeutic interventions for cancer. Sponsors: This resource is supported by the U.S. National Institues Of Health.

Proper citation: CGEMS (RRID:SCR_008445) Copy   

•   Source: SciCrunch Registry

http://www.nia.nih.gov/research/dab/aged-rodent-tissue-bank-handbook/tissue-arrays

Offer high-throughput analysis of tissue histology and protein expression for the biogerontology research community. Each array is a 4 micron section that includes tissue cores from multiple tissues at multiple ages on one slide. The arrays are made from ethanol-fixed tissue and can be used for all techniques for which conventional tissue sections can be used. Ages are chosen to span the life from young adult to very old age. (available ages: 4, 12, 18, 24 and 28 months of age) Images of H&E stained punches are available for Liver, Cardiac Muscle, and Brain. The NIA aged rodent tissue arrays were developed with assistance from the National Cancer Institute (NCI) Tissue Array Research Program (TARP), led by Dr. Stephen Hewitt, Director. NCI TARP contains more information on tissue array construction, protocols for using arrays, and references. Preparation and Product Description Tissue arrays are prepared in parallel from different sets of animals so that experiments can be conducted in duplicate, with each array using unique animals with a unique product number. The product descriptions page describes each array, including: * Strain * Gender * Ages * Tissues * Animal Identification Numbers

Proper citation: Aged Rodent Tissue Arrays (RRID:SCR_007332) Copy   

•   Source: SciCrunch Registry

http://www.predect.eu/

Project that aims to create more appropriate in vitro platforms for target validation and drug discovery for breast, prostate and lung cancers. Laboratory platforms to validate whether target modulation would provide a clinical benefit are usually highly reductionist, often using long-established cell lines growing in 2 dimensions in vitro. These models do not reflect the complexity and heterogeneity of a tumor in situ, where biochemical pathways are wired with connections to the complex tumor environment provided by the stroma. PREDECT has the goal of comparing the pathological and molecular profiles of novel in vitro platforms with those of human tumors. Because obtention of clinical material presents both logistics and quality problems for ongoing and intense studies of target validation, PREDECT aims to use material from genetically engineered mouse models, and some advanced xenografts, whose pathology and molecular profiles closely match cohorts of human tumors. PREDECT hopes to provide more appropriate in vitro platforms both for target validation and subsequent preclinical studies which will replace a current cascade of tests which are poorly predictive of clinical activity. The project is expected to shift paradigms in cell biology as well as in preclinical target validation where it should permit greater predictivity of drug efficacy in patient cohorts.

Proper citation: PREDECT (RRID:SCR_003883) Copy   

•   Source: SciCrunch Registry

http://www.sbur.org/

The Society for Basic Urologic Research (SBUR) is a society of scientists whose expertise includes the study of urologic cancers (prostate, bladder, kidney, testis, penis), the biology of prostate growth, kidney and bladder function, autoimmune urologic diseases, infectious diseases, neuro-urologic diseases, male reproductive biology, infertility and erectile dysfunction. Members include molecular biologists, immunologists, epidemiologists, oncologists, biochemists and clinical urologic scientists. SBUR members serve on a wide variety of advisory panels, study sections, editorial boards and in the pharmaceutical industry. The SBUR organizes two annual meetings to share new findings at a multidisciplinary level, to promote interaction among members and other interested scientists and to highlight new areas of research and funding opportunities. The Society was organized to address the following: * To provide a forum for the presentation and discussion of basic scientific topics related to urology * To develop educational forums concerning scientific advancements related to the field of urology * To promote collaborative investigations among member scientists with an emphasis on the interchange of expertise among clinical and basic scientists * To promote the communication and interests of urologic disease investigators with national funding agencies, industry representatives and academic institutions with regards to urology related research * To serve as a resource for research information and expertise to clinical urologists through the American Urological Association

Proper citation: SBUR - Society for Basic Urologic Research (RRID:SCR_005856) Copy   

•   Source: SciCrunch Registry

http://www2.niddk.nih.gov/NR/rdonlyres/8E99FCF4-8A92-43EE-8E47-5B70D634938A/0/AUABPH.pdf

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Adapted from the American Urology Association Symptom Score for Benign Prostatic Hyperplasia, this chart will assist physicians, researchers, and patients in assessing the severity of the problem.

Proper citation: Symptom Score for Benign Prostatic Hyperplasia (RRID:SCR_000127) Copy   

•   Source: SciCrunch Registry

http://icmic.rad.jhmi.edu/

The vision of the JHU ICMIC is to combine state-of-the-art imaging capabilities with powerful molecular biology techniques to define strategies with intent to cure. It has drawn upon its human resources at JHU to create a center consisting of a multidisciplinary group of premier individuals with diverse skills focused on translating molecular capabilities into imaging possibilities with the single purpose of understanding and curing cancer. Nearly all of the investigators participating in this ICMIC have interactive collaborative projects with one or more of the other investigators. The synergism generated by the collective skills of this unique group of individuals will lead to significant advances in the understanding of cancer and its treatment. The JHU ICMIC structure consists of four interactive and closely related research components focused on hypoxia, HIF-1, and exploiting the hypoxia response element to target cancer cells through choline kinase inhibition. These research components are anchored by the participation of world renowned expertise in HIF-1. The research components utilize MR, PET and Optical Imaging technology to understand cancer vascularization, invasion and metastasis, to achieve effective cancer therapy. The center has selected developmental projects which are highly relevant to the goals of the ICMIC and interactive with the research components. Five resources devoted to adminstration, molecular biology, imaging, probes, and translational application provide the infrastructure to support the research activities of the ICMIC. Research Components in the JHU ICMIC: - Combining Anti-angiogenic therapy with siRNA targeting of choline kinase. - Imaging the Role of HIF-1 in Breast Cancer Progression - Imaging and Targeting Hypoxia in Solid Tumors - Molecular and Functional Imaging of the HER-2/neu Receptor The following are developmental projects currently taking place in ICMIC 1. Receptor imaging using nonparamagnetic MRI contrast agents (2003) 2. New imaging agents for prostate cancer (2003) 3. Non-invasive monitoring of therapeutic effect of siRNA-mediated radiation sensitization in human prostate cancer xenografts (2003) 4. Imaging of the endothelin receptor in cancer (2003) 5. Imaging studies of c-myc regulation of tumor metabolism (2003) 6. Imaging studies of anti-tumorigenic effects of anti-oxidants in vivo (2005) 7. Molecular Imaging with Magnetic Resonance Microsystems (2005) 8. Endogenous angiogenesis inhibitors (2005) 9. MR imaging and spectroscopy in detection and localization of prostate cancer: a prospective trial in patients undergoing cystoprostatectomy and radical prostatectomy. (2005) 10. A versatile visualization system for the analysis of multi-modality and multidimensional cancer imaging (2007) 11. Non-invasive imaging of CXCR4 expression in breast cancer (2007)

Proper citation: John Hopkins University, In-Vivo Cellular Molecular Imaging Center (RRID:SCR_013198) Copy   

•   Source: SciCrunch Registry

http://www.bumc.bu.edu/busm-pathology/pathology-core-services/biospecimen-archive-research-core-barc/

Biospecimen repository of normal and diseased human material from a variety of tissues and conditions along with clinical annotation. Both frozen aliquots and paraffin embedded tissue are available. Biospecimens are available to qualified researchers with IRB approval. * Preliminary inquires please contact Cheryl Spencer at cheryl.spencer (at) bmc.org

Proper citation: Boston University Biospecimen Archive Research Core (RRID:SCR_005363) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103697&l=en

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd,2023. Recently it has been discovered that specific Single Nucleotide Polymorphisms (SNPs) may elevate the risk of developing prostate cancer. This study aims at investigating whether it is possible to use these SNPs in a clinical setting in order to sharpen the diagnostic tools when investigating if a man has prostate cancer. By collecting blood from men who have undergone a needle biopsy of the prostate and do a SNP analysis of their genes and compare this with the result of the biopsy and PSA result we hope to be able to develop a test that is more specific than the routine that is being used today. Sample types: * EDTA whole blood * DNA Number of sample donors: 5321 (June 2010)

Proper citation: SPSAC - Stockholm PSA Cohort (RRID:SCR_006042) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103566&l=en

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd, 2023. The ICAP - Integrated analysis of prostate cancer study aims at identifying a set of biomarkers with high prognostic value for prostate cancer progression. These biomarkers will be used to customize treatment and to identify patients with high risk of recurrent disease. Sample types: * EDTA whole blood * DNA Number of sample donors: 505 (sample collection completed)

Proper citation: ICAP - Integrated analysis of prostate cancer (RRID:SCR_006035) Copy   

•   Source: SciCrunch Registry

http://www.procap.ki.se/procap_studie_info.htm

PROCAP is a study of the importance of lifestyle and genetic factors in the progression of localized cancer of the prostate. Our study hypothesis is that the likelihood of disease recurrence of prostate cancer is modified or determined by genetic variation in the human genome and/or lifestyle factors. To be able to test our hypothesis, we are using a large, population-based cohort of men with localized prostate cancer in Sweden, recruited in 1997-2002, from which detailed clinical information and data on progression already have been collected. From this cohort, we are collecting lifestyle data and blood samples from 8,500 men. If men with progressive prostate cancer could be identified on their genetic make-up, they could be given additional therapies targeted specifically at prostate cancer progression or monitored even more frequently so that progressions could be treated even earlier. If lifestyle factors are important, these results have an impact on recommendations given to men with newly diagnosed prostate cancer. In the study, we are asking the study persons to fill in an Internet-based questionnaire focusing on diet and physical activity and we ask them to leave 2 test tubes of blood at their local urologist/health care center. The pilot study has recently been completed and evaluated and the remaining 7,500 men in the cohort will be included during 2007 and 2008. So far, we have a response rate of approximately 85% on the blood samples. The response rate for the questionnaire is approximately 80% (both in the web based and paper based versions combined). Genotyping and analysis will begin in the fall of 2008. Sample types: * EDTA whole blood * Plasma * DNA Number of sample donors: 5492 (sample collection completed)

Proper citation: KI Biobank - PROCAP (RRID:SCR_006038) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/cancer-of-the-prostate-in-sweden-caps

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd,2023. We have completed the recruitment of this population-based prostate cancer case-control study, one of the largest prostate cancer case-control study populations available so far. This study population was recruited in two phases. The inclusion and exclusion criteria were the same for the first (CAPS1) and second phase (CAPS2), except for the timeframe. In total, 3,030 cases and 1,960 controls participated in CAPS donating blood samples and answering a questionnaire during 2001-2003. In addition we have detailed clinical information on all 3,000 cases. With data generated from CAPS we have 25 published papers and 10 manuscripts since 2004. During 2006 we completed a record linkage to the Cause of Death Registry to determine the cause of death for all participants. We could conclude that 347 of the cases in CAPS had died of prostate cancer. The CAPS study has provided data to several new studies on markers on prostate cancer progression. Sample types: * EDTA whole blood * DNA Number of sample donors: 5015 (sample collection completed)

Proper citation: Cancer of the Prostate in Sweden (CAPS) (RRID:SCR_006033) Copy   

•   Source: SciCrunch Registry

http://kidney.niddk.nih.gov/statistics/uda/

A report incorporating current and retrospective data on all aspects of the epidemiology, practice patterns, costs, and impact of urologic diseases in the United States and is intended for use by public officials, nongovernment organizations, the media, academic researchers, health professionals, and the public. The UDA compendium consists of data tables annotated in chapters that amplify the data analyses. The objectives of the UDA project include: secondary data analyses of: changes in the overall healthcare burden for individual urologic diseases, in physician practice patterns for each urologic disease, and in demographics of persons with urologic disease, the impact of specific urologic diseases, especially diseases of the prostate, on the minority populations of the U.S., and documentation of new and evolving therapies for urologic disease and their cost.

Proper citation: Urologic Diseases in America (RRID:SCR_006644) Copy   

•   Source: SciCrunch Registry

http://netbio.bgu.ac.il/tissuenet/

Database of human tissue protein-protein interactions (PPIs) that associates each interaction with human tissues that express both pair mates. This was achieved by integrating current data of experimentally detected PPIs with extensive data of gene and protein expression across 16 main human tissues. Users can query TissueNet using a protein and retrieve its PPI partners per tissue, or using a PPI and retrieve the tissues expressing both pair mates. The graphical representation of the output highlights tissue-specific and tissue-wide PPIs. Thus, TissueNet provides a unique platform for assessing the roles of human proteins and their interactions across tissues.

Proper citation: TissueNet - The Database of Human Tissue Protein-Protein Interactions (RRID:SCR_002052) Copy   

•   Source: SciCrunch Registry

http://www.rad.upenn.edu/sbia/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 2, 2023. A section of the Penn department of radiology, it is devoted to the development of computer-based image analysis methods and their application to clinical research studies. Image analysis methodologies include image registration, segmentation, population-based statistical analysis, biophysical modeling of anatomical deformations, and high-dimensional pattern classification. Clinical research studies spans a variety of clinical areas and organs, and they include brain diseases such as Alzheimer's disease and schizophrenia, evaluation of treatment effects in large clinical trials, diagnosis of cardiac diseases, and diagnosis prostate, breast and brain cancer. SBIA also performs small animal imaging research aiming to understand brain development in mouse models. It has multiple resources which can be accessed by researcher.

Proper citation: SBIA (RRID:SCR_013628) Copy   

•   Source: SciCrunch Registry

http://cancer.gov/cancertopics/pdq/cancerdatabase

NCI''s comprehensive cancer database that contains summaries on a wide range of cancer topics; a registry of 8,000+ open and 19,000+ closed cancer clinical trials from around the world; a directory of professionals who provide genetics services; the NCI Dictionary of Cancer Terms, with definitions for 6,800+ cancer and medical terms; and the NCI Drug Dictionary, which has information on 2,300+ agents used in the treatment of cancer or cancer-related conditions. The PDQ cancer information summaries are peer reviewed and updated monthly by six editorial boards comprised of specialists in adult treatment, pediatric treatment, supportive care, screening and prevention, genetics, and complementary and alternative medicine. The Boards review current literature from more than 70 biomedical journals, evaluate its relevance, and synthesize it into clear summaries. Many of the summaries are also available in Spanish.

Proper citation: Physician Data Query (RRID:SCR_006833) Copy   

•   Source: SciCrunch Registry

http://tvmouse.ucdavis.edu/anatomy/

Access to Quicktime movies of histologic mouse anatomy including heart / lung, kidney, mammary gland, lymph node, prostate, spleen, liver, salivary glands, and 3-D wire model based on MRI sections; a Quicktime mouse radiographic atlas of skeletal anatomy containing a series of radiographic images with color overlays and labels; and a table containing a comparison between mouse and human anatomy. Special topics include the virtual necroscopy. Anatomic systems cover the central nervous system, male genital-urinary tract, female genital-urinary tract, mammary, kidney, skeletal, cardiovascular, gastrointestinal, and respiratory systems. The pathology and imaging section includes anatomy, histology, comparative imaging, physiology, pathology, comparative mammary, comparative prostate, GEM, and an image archive. These pages were put together as a pilot demonstration by Dr. Robert Cardiff, UCD Center for Comparative Medicine with the collaboration of Dr. Michael Paulus, Oak Ridge National Laboratories,MicroCat Group, Dr. Allan Johnson, Duke University Center for In Vivo Microscopy, and Drs. Steve Griffey, Gary Henderson and Tom Jue, University of California, Davis. This is a work in progress and for demonstration purposes.

Proper citation: Visible Mouse Anatomy (RRID:SCR_001603) Copy   

•   Source: SciCrunch Registry

http://www2.bsc.gwu.edu/bsc/oneproj.php?pkey=8

Multi-center double-masked, placebo-controlled randomized clinical trial designed to evaluate the long-term efficacy of finasteride, or doxazosin, or the combination of both, in delaying or preventing the clinical progression of symptomatic benign prostatic hyperplasia (BPH). MTOPS was the largest and longest study to test whether drug therapy can prevent or delay the noncancerous growth of the prostate. A unique feature of MTOPS that has not been done in prior studies of pharmacotherapy of BPH is the biopsy substudy. A total of 1,082 volunteers from the 2,931 participants randomized during the full-scale phase are currently participating in this substudy. Biopsies of the prostate will be obtained on these volunteers at predetermined times during the course of the trial to evaluate the status of the prostate at key event times. The purpose of the substudy was to provide additional information regarding the histopathobiology of BPH and to test existing biomarkers for their prognostic ability regarding response to drug therapy.

Proper citation: Medical Therapy of Prostatic Symptoms (RRID:SCR_001556) Copy   

•   Source: SciCrunch Registry

http://archives.niddk.nih.gov/patient/camus/camus.aspx

Randomized, multicenter, double blind, placebo controlled clinical trial of phytotherapy for benign prostate symptoms among men. The CAMUS trial will test Saw palmetto in about 369 men. Men who decide to be part of the CAMUS trial will be given one out of two possible treatments at random. One out of every two men would get an inactive placebo treatment. One out of every two men would get Saw palmetto pills. This kind of scientific study is the best way to find out if the plant extracts really work to prevent men with benign prostatic hyperplasia (BPH) from getting worse. During the study, men will not know which of the two treatments they are assigned to. They will be followed very closely by a study team every 12 weeks to see how they are doing. Men in the CAMUS trial will be studied over 72 weeks. Ten clinical centers will participate in the trial. They are located at: Columbia University, NY, NY; New York University, NY, NY; University of Texas Southwestern Medical Center, Dallas, Texas; University of Colorado, Denver, CO; Washington University, St. Louis, MO; Yale University, New Haven, CT; Queens University, Hamilton, Ontario, Canada; Northwestern University, Chicago, IL; University of Maryland, Baltimore, MD; University of California at San Francisco, San Francisco, CA.

Proper citation: Complementary and Alternative Medicine for Urological Symptoms (RRID:SCR_007131) Copy   

•   Source: SciCrunch Registry